Viral vector manufacturers are looking for ways to leverage existing and new platforms with fit-for-purpose reagents (cell lines, plasmid DNA [pDNA], media, transfection reagent) to identify and optimize critical process parameters across all unit operations. Both upstream steps like transient transfection and the various downstream purification, final formulation, and fill/finish steps have deep impacts on process economics. Double the production, lower the cost To address current limits in rAAV viral vector yields and industrial scalability for suspension cell culture systems,…